Skip to main content
Evidence Snapshot

Serine/threonine-protein kinase N2

CHEMBL3032 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3032
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase N2 as ChEMBL target CHEMBL3032, mapped to UniProt Q16513. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase N2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL3032
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q16513
Serine/threonine-protein kinase N2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Serine/threonine-protein kinase N2 matters

As of 2026-09-14

Serine/threonine-protein kinase N2 is reviewed as Serine/threonine-protein kinase N2 (UniProt Q16513); the current evidence base includes 11 approved drugs, 1614 compounds, and 326 assays, with lead potency reaching pChEMBL 9.1.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 11 approved drugs, 1614 compounds, and 326 assays for this target. The dominant activity type is KI. CHEMBL1980995 is the current potency anchor at pChEMBL 9.1.

Use CHEMBL1980995 as the tractability anchor when discussing potency (pChEMBL 9.1).

Activity source · ChEMBL 36 via Core Engine
11 approved pChEMBL 9.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Serine/threonine-protein kinase N2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q16513, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1614
Total Compounds
326
Total Assays
11
Approved Drugs
IC50: 103.0, KI: 733.0, KD: 366.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL1980995
 9.1 Ki —
No preferred name
CHEMBL603469
 8.7 Kd Clinical
No preferred name
CHEMBL388978
 8.7 IC50 —
No preferred name
CHEMBL1968930
 8.6 Ki —
No preferred name
CHEMBL1969588
 8.6 Ki —

Approved Drugs

Structure Compound First Approval
MIDOSTAURIN
CHEMBL608533
 2017
BARICITINIB
CHEMBL2105759
 2017
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:33Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3032